Search

Home > Diabetes Knowledge into Practice Podcast > Multifactorial effects across pharmacotherapies: clinical data and what they mean
Podcast: Diabetes Knowledge into Practice Podcast
Episode:

Multifactorial effects across pharmacotherapies: clinical data and what they mean
Category: Health
Duration: 00:23:39
Publish Date: 2020-04-14 04:00:00
Description:

A mountain of data exist for each antihyperglycaemic agent, from metformin through to the most recently   approved agent. Considering all these data, what are the most significant   observations to date?

Join Professor Jens Juul Holst from the   University of Copenhagen for a summary of data on DPP-4 inhibitors, SGLT2   inhibitors and GLP-1 receptor agonists, including a particular focus on   within-class differences and whether oral vs injectable formulations have   different effects


References


- Pinto LC, et al. Diabetol Metab Syndr. 2015; 7(Suppl 1): A58

- Craddy P, et al. Diabetes Ther. 2014;5(1):1-41.

- Uccellatore A, et al. Diabetes Ther. 2015;6(3):239-56

- Nauck MA, et al. Diabetologia. 2016; 59(2):266-74.

- Aroda VR, et al. Diabetes Obes Metab. 2020; 22(3):303-314

- Ahrén B. Front Endocrinol (Lausanne). 2019;10:376 

- Rosenstock J, et al. JAMA. 2019 Sep 19. [Epub ahead of print]

- Kristensen SL. Lancet Diabetes Endocrinol. 2019; 7(10):776-785

- Romera I, et al. Diabetes Therapy 2019;   10:5-19

- McMurray JJV, et al. N Engl J Med 2019;   381:1995-2008

- Perkovic V, et al. N Engl J Med 2019;   380:2295-2306

- Fitchett D, et al. Diabetes Obes Metab. 2019;21   Suppl 2:34-42.


This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.
Total Play: 0